ClinicalTrials.gg
Not yet recruitingNCT07747207Updated Aug 10, 2026

PULSTA TPV Observational Study

An observational study in Heart Disease, sponsored by Taewoong Medical Co., Ltd.. Not yet recruiting at 9 sites in 6 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Heart Diseases with a site in Korea, Republic of — 8 open to participants now, 10 under way, 2 of them phase 3. Heart Diseases · Korea, Republic of.

Started
2026
the only one that year
Observational
8 of 31
3 open now
Registered
31st of 31
by date
Lead sponsor
2 of 31
Taewoong Medical Co., Ltd.

Among the 31 studies in Heart Diseases with a site in Korea, Republic of, this one is the only one that started in 2026, is one of 8 observational ones, and was the 31st registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

8 of the 31 studies in Heart Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Heart Diseases with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of the study is to determine the long-term follow-up clinical outcomes, effectiveness, and safety data of the PULSTA Transcatheter Pulmonary Valve (TPV) implantation in a real-world situation

Read the detailed description

The PULSTA TPV is a self-expandable valve with flared-ends to adapt to the larger native right ventricular outflow tract (RVOT) and is using a relatively low profile delivery catheter from knitted nitinol wire backbone and trileaflets made from treated porcine pericardial tissue, and a delivery system, which provides access to the right ventricular outflow tract through blood vessels. This registry will collect real-world clinical data on patients undergoing PULSTA TPV implantation at discharge and at 1 month, 6 months, and annually for up to 5 years after implantation.

03

Conditions studied

  • Heart Disease

Keywords

  • Pulmonary Valve Regurgitation
  • Pulmonary Valve Stenosis
  • Tetralogy of Fallot
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with right ventricular outflow tract (RVOT) dysfunction who are considered eligible for percutaneous pulmonary valve implantation (PPVI) with the PULSTA TPV according to the approved indication and routine clinical practice at participating centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moderate to severe pulmonary regurgitation and/or pulmonary stenosis who undergo transcatheter pulmonary valve implantation using the PULSTA Transcatheter Pulmonary Valve(TPV).
  • Patients who are willing to participate in the study and who have voluntarily provided written .

Exclusion criteria

Exclusion Criteria:

  • Patients who have not signed
  • Patients who are for the implantation per the device's Instructions for Use.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • PULSTA TPV Recipients

    Single-arm cohort consisting of all eligible patients undergoing percutaneous pulmonary valve implantation(PPVI) with the PULSTA TPV as part of routine clinical care

06

What researchers measure

Primary outcomes

  1. Procedural / device-related serious adverse events at 12 months

    Time frame: 12 months

  2. Hemodynamic functional improvement at 12 months

    Hemodynamic functional improvement is defined as the achievement of both of the following criteria: * Mild or less pulmonary regurgitation measured by echocardiography AND * Mean Right Ventricular Outflow Tract(RVOT) pressure gradient measured by echocardiography ≤35mmHg

    Time frame: 12 months

Secondary outcomes

  1. Procedural success

    Procedural success is defined as the Transcatheter Pulmonary Valve(TPV) implant in on the desired site, Right ventricle-Pulmonary artery (RV-PA) peak systolic pressure gradient \<35mmHg by cardiac catheterization, less mild pulmonary regurgitation by angiography, and freedom from explantation of the TPV at 24 hours following implantation.

    Time frame: 24 hours

  2. Hemodynamic function at all follow-up visits

    Hemodynamic function will be assessed including: * Peak RVOT pressure gradient (by echocardiography) * Mean RVOT pressure gradient (by echocardiography)

    Time frame: 5 years

  3. Severity of pulmonary regurgitation (by echocardiography)

    Severity of pulmonary regurgitation will be measured by Doppler echocardiography and classified into none, trace/trivial, mild, moderate, and severe.

    Time frame: 5 years

  4. NYHA functional classification

    Clinical outcome will be assessed as per the New York Heart Association (NYHA) functional classification at all follow-up visits and will be compared to baseline values.

    Time frame: 5 years

  5. Freedom from death

    Frequency of all cause / cardiac / non-cardiac / procedural-related / device-related deaths during the 5-year follow-up period

    Time frame: 5 years

  6. Freedom from re-operation

    Reoperation is defined as open surgery that alters or adjusts, or replaces a previously implanted PULSTA

    Time frame: 5 years

  7. Freedom from catheter re-intervention

    Any interventional catheter procedure (e.g. balloon angioplasty) that alters or adjusts, or replaces a previously implanted PULSTA TPV

    Time frame: 5 years

  8. Freedom from TPV dysfunction

    Moderate or greater pulmonary regurgitation, clinically significant RVOT obstruction (mean RVOT gradient \>35 mmHg), or any valve-related event requiring re-intervention or re-operation

    Time frame: 5 years

  9. Incidence of procedural- and device-related adverse events

    Time frame: 5 years

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2028, 21 months later.

Of 54 industry-sponsored observational studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 65. This study's planned 21 months is below that.

Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Jul 2028
CompletionEst.
Oct 2033
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07747207
Collaborators
Avania
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Oct 2033 (estimated)
Last update
Aug 10, 2026

Study contacts

Jang Mi Ko
Contact
jmko@stent.net
+82 31 904 6187 ext. 637
Hyejin Roh
Contact
hjroh@stent.net
+82 70 4649 1624 ext. 628
Mario Carminati
study chair · Niguarda Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion